Risk Factors for Bleeding and Thromboembolic Events in Patients With Chronic Kidney Disease on Maintenance Hemodialysis: A Retrospective Case-Control Study Based on the Roxadustat User Population.
Аннотация
BACKGROUND
Chronic kidney disease (CKD) often necessitates maintenance hemodialysis, a process associated with significant complications such as bleeding and thromboembolic events. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is emerging as a promising alternative for managing anemia in CKD. This study aims to assess risk factors for bleeding and thromboembolic events in CKD patients on hemodialysis, focusing on Roxadustat use.
METHODS
We conducted a retrospective case-control study of 229 CKD patients undergoing maintenance hemodialysis for at least 1 year. Patients were categorized based on the occurrence of bleeding (n = 51) or thromboembolic events (n = 58), compared to those without such events (n = 120). Baseline demographics, laboratory markers, and Roxadustat usage were evaluated. Logistic regression analyses were used to identify independent risk factors for bleeding and thromboembolic events.
RESULTS
Roxadustat usage was significantly less common in patients who experienced bleeding events (64.71%) compared to the no occurrence group (85.00%, p = 0.003), and similarly less common in those with thromboembolic events (67.24%) compared to the no occurrence group (85.00%, p = 0.006). Lower baseline hemoglobin levels were associated with bleeding events (p = 0.007), while higher baseline hemoglobin levels were associated with thromboembolic events (p = 0.008). Elevated baseline hs-CRP levels were significant in both the bleeding group (p = 0.001) and thromboembolic group (p = 0.019). TSAT below 30% at baseline was also a significant factor in both the bleeding group (p = 0.004) and thromboembolic group (p = 0.025). Multivariate analyses indicated that Roxadustat use significantly reduced bleeding risk (OR = 0.376, p = 0.024) and thromboembolic events (OR = 0.287, p = 0.003).
CONCLUSION
Roxadustat use was associated with a lower risk of bleeding and thromboembolic events in CKD patients on hemodialysis. This association may be mediated through the stabilization of hemoglobin levels, modulation of iron metabolism, and attenuation of inflammation.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.